{"id":"butenafine","rwe":[{"pmid":"41730890","year":"2026","title":"Direct synthesis of bicyclo[1.1.1]pentane (BCP) boronates from carboxylic acids.","finding":"","journal":"Nature communications","studyType":"Clinical Study"},{"pmid":"41400362","year":"2026","title":"An in vitro release test method with Immersion Cells for evaluation of drug release performance of butenafine hydrochloride cream.","finding":"","journal":"Drug development and industrial pharmacy","studyType":"Clinical Study"},{"pmid":"41378809","year":"2025","title":"A Case of Tinea Nigra in Southern China.","finding":"","journal":"The American Journal of dermatopathology","studyType":"Clinical Study"},{"pmid":"40733240","year":"2025","title":"Extended Antimicrobial Profile of Chromone-Butenafine Hybrids.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"40657696","year":"2025","title":"Synthesis of N-Methylated Amines via Reduction of Carbamates Using Amidophosphine Borane.","finding":"","journal":"The Journal of organic chemistry","studyType":"Clinical Study"}],"_fda":{"id":"3906a83a-cbe3-2864-e063-6394a90a4be2","set_id":"0841f741-6409-4d93-a6a7-901808f77bcd","openfda":{"upc":["0041220573646"],"unii":["R8XA2029ZI"],"route":["TOPICAL"],"rxcui":["1298448"],"spl_id":["3906a83a-cbe3-2864-e063-6394a90a4be2"],"brand_name":["Athletes Foot Ultra"],"spl_set_id":["0841f741-6409-4d93-a6a7-901808f77bcd"],"package_ndc":["37808-013-02"],"product_ndc":["37808-013"],"generic_name":["BUTENAFINE HYDROCHLORIDE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["BUTENAFINE HYDROCHLORIDE"],"manufacturer_name":["H E B"],"application_number":["ANDA205181"],"is_original_packager":[true]},"purpose":["Purpose Antifungal"],"version":"2","stop_use":["Stop use and ask a doctor if too much irritation occurs or irritation gets worse"],"warnings":["Warnings For external use only Do not use on nails or scalp in or near the mouth or the eyes for vaginal yeast infections When using this product do not get into the eyes. If eye contact occurs, rinse thoroughly with water. Stop use and ask a doctor if too much irritation occurs or irritation gets worse Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."],"questions":["Questions? Call 1-866-923-4914"],"do_not_use":["Do not use on nails or scalp in or near the mouth or the eyes for vaginal yeast infections"],"when_using":["When using this product do not get into the eyes. If eye contact occurs, rinse thoroughly with water."],"effective_time":"20250703","active_ingredient":["Active ingredient Butenafine hydrochloride 1%"],"inactive_ingredient":["Inactive ingredients benzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23) cetyl ether, propylene glycol dicaprylate, purified water, sodium benzoate, stearic acid, trolamine, white petrolatum"],"storage_and_handling":["Other information do not use if seal on tube is broken or not visible store between 20° to 25° C (68° to 77° F)"],"indications_and_usage":["Uses cures most athlete's foot between the toes. Effectiveness on the bottom or sides of foot is unknown. cures most jock itch and ringworm relieves itching, burning, cracking, and scaling which accompany these conditions"],"spl_unclassified_section":["Drug Facts"],"dosage_and_administration":["Directions adults and children 12 years and older: use the tip of the cap to break the seal and open the tube wash the affected skin with soap and water and dry completely before applying for athlete's foot between the toes: apply to affected skin between and around the toes twice a day for 1 week (morning and night), or once a day for 4 weeks, or as directed by a doctor. Wear well-fitting, ventilated shoes. Change shoes and socks at least once daily. Apply between and around the toes 1 week twice a day or 4 weeks once a day for jock itch and ringworm: apply once a day to affected skin for 2 weeks or as directed by a doctor. wash hands after each use children under 12 years: ask a doctor image"],"spl_product_data_elements":["Athletes Foot Ultra Butenafine Hydrochloride BENZYL ALCOHOL CETYL ALCOHOL GLYCERIN GLYCERYL STEARATE SE CETETH-23 PROPYLENE GLYCOL DICAPRYLATE WATER SODIUM BENZOATE STEARIC ACID TROLAMINE PETROLATUM BUTENAFINE HYDROCHLORIDE BUTENAFINE"],"keep_out_of_reach_of_children":["Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 12 g Tube Carton Compare to Lotrimin Ultra ® * active ingredient NDC 37808-013-02 H-E-B ® Clinically Proven to Cure Most Athlete's Foot between the Toes Athlete's Foot Cream Ultra Butenafine Hydrochloride Cream 1% Antifungal NET WT 12 g (0.42 oz) PRINCIPAL DISPLAY PANEL - 12 g Tube Carton"]},"tags":[{"label":"Benzylamine Antifungal","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 2D6","category":"target"},{"label":"CYP2D6","category":"gene"},{"label":"SLC6A4","category":"gene"},{"label":"ADRA2A","category":"gene"},{"label":"D01AE23","category":"atc"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Pityriasis versicolor","category":"indication"},{"label":"Tinea corporis","category":"indication"},{"label":"Tinea cruris","category":"indication"},{"label":"Tinea pedis","category":"indication"},{"label":"Bayer Healthcare Llc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antifungal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"180 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"59 reports"},{"date":"","signal":"PRODUCT USE ISSUE","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"29 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"21 reports"},{"date":"","signal":"DRUG EFFECT DECREASED","source":"FDA FAERS","actionTaken":"19 reports"},{"date":"","signal":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"19 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"19 reports"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Bayer","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$0.3090/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$113","description":"BUTENAFINE HCL 1% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BUTENAFINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:11:26.276961+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Butenafine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:11:34.294442+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:11:32.930360+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:11:24.927073+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTENAFINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:11:33.715934+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:23.736889+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:23.736940+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:11:35.216026+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL990/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:11:34.182707+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA205181","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:23.736951+00:00"}},"allNames":"mentax","offLabel":[],"synonyms":["KP-363","KP 363","butenafine","butenafine hydrochloride","butenafine HCl"],"timeline":[{"date":"1996-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MYLAN to Bayer Healthcare Llc"},{"date":"1996-10-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Mylan)"},{"date":"2002-10-17","type":"positive","source":"FDA Orange Book","milestone":"Mentax-Tc approved — 1%"},{"date":"2017-11-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Mentax (Butenafine) is a benzylamine antifungal medication originally developed by Mylan and currently owned by Bayer Healthcare LLC. It targets the cytochrome P450 2D6 enzyme and is used to treat various fungal infections such as pityriasis versicolor, tinea corporis, tinea cruris, and tinea pedis. Mentax is a small molecule modality that was FDA-approved in 1996 and is now off-patent with no active Orange Book patents. It is available as a generic medication from a single manufacturer. As an off-patent medication, Mentax is widely available and has a well-established safety profile.","brandName":"Mentax","ecosystem":[{"indication":"Pityriasis versicolor","otherDrugs":[{"name":"acrisorcin","slug":"acrisorcin","company":"Schering"},{"name":"carbamide","slug":"carbamide","company":"Hospira"},{"name":"ciclopirox","slug":"ciclopirox","company":"Medimetriks Pharms"},{"name":"clotrimazole","slug":"clotrimazole","company":""}],"globalPrevalence":null},{"indication":"Tinea corporis","otherDrugs":[{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"},{"name":"ciclopirox","slug":"ciclopirox","company":"Medimetriks Pharms"}],"globalPrevalence":null},{"indication":"Tinea cruris","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"},{"name":"ciclopirox","slug":"ciclopirox","company":"Medimetriks Pharms"},{"name":"clioquinol","slug":"clioquinol","company":""}],"globalPrevalence":null},{"indication":"Tinea pedis","otherDrugs":[{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone dipropionate","slug":"betamethasone-dipropionate","company":"Schering"},{"name":"ciclopirox","slug":"ciclopirox","company":"Medimetriks Pharms"}],"globalPrevalence":640000000}],"mechanism":{"target":"Cytochrome P450 2D6","novelty":"Follow-on","targets":[{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"ACHE","source":"DrugCentral","target":"Acetylcholinesterase","protein":"Acetylcholinesterase"}],"modality":"Small Molecule","drugClass":"Benzylamine Antifungal","explanation":"","oneSentence":"","technicalDetail":"Butenafine exerts its antifungal effects by inhibiting the enzyme cytochrome P450 2D6, which is involved in the biosynthesis of ergosterol, a critical component of fungal cell membranes."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Butenafine","title":"Butenafine","extract":"Butenafine, sold under the brand names Lotrimin Ultra, Mentax, and Butop, is a synthetic benzylamine derived antifungal drug."},"commercial":{"launchDate":"1996","_launchSource":"DrugCentral (FDA 1996-10-18, MYLAN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/444","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BUTENAFINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTENAFINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Butenafine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:06:36.056696","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:11:37.403669+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"undecylenic acid","drugSlug":"undecylenic-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"chlorphenesin carbamate","drugSlug":"chlorphenesin-carbamate","fdaApproval":"1965-06-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"haloprogin","drugSlug":"haloprogin","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"selenium sulfide","drugSlug":"selenium-sulfide","fdaApproval":"1951-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ciclopirox","drugSlug":"ciclopirox","fdaApproval":"1982-12-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"terbinafine","drugSlug":"terbinafine","fdaApproval":"1992-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tolnaftate","drugSlug":"tolnaftate","fdaApproval":"","relationship":"same-class"},{"drugName":"flucytosine","drugSlug":"flucytosine","fdaApproval":"1971-11-26","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"naftifine","drugSlug":"naftifine","fdaApproval":"1988-02-29","patentExpiry":"Jan 31, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tavaborole","drugSlug":"tavaborole","fdaApproval":"2014-07-07","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"butenafine","indications":{"approved":[{"name":"Pityriasis versicolor","source":"DrugCentral","snomedId":56454009,"regulator":"FDA","eligibility":null},{"name":"Tinea corporis","source":"DrugCentral","snomedId":84849002,"regulator":"FDA","eligibility":null},{"name":"Tinea cruris","source":"DrugCentral","snomedId":399029005,"regulator":"FDA","eligibility":null},{"name":"Tinea pedis","source":"DrugCentral","snomedId":6020002,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":640000000,"prevalenceMethod":"curated","prevalenceSource":"BMC Public Health, 2025 (PMID:40993673)"}],"offLabel":[],"pipeline":[]},"currentOwner":"Bayer Healthcare Llc","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"undecylenic-acid","brandName":"undecylenic acid","genericName":"undecylenic acid","approvalYear":"","relationship":"same-class"},{"drugId":"chlorphenesin-carbamate","brandName":"chlorphenesin carbamate","genericName":"chlorphenesin carbamate","approvalYear":"1965","relationship":"same-class"},{"drugId":"haloprogin","brandName":"haloprogin","genericName":"haloprogin","approvalYear":"","relationship":"same-class"},{"drugId":"selenium-sulfide","brandName":"selenium sulfide","genericName":"selenium sulfide","approvalYear":"1951","relationship":"same-class"},{"drugId":"ciclopirox","brandName":"ciclopirox","genericName":"ciclopirox","approvalYear":"1982","relationship":"same-class"},{"drugId":"terbinafine","brandName":"terbinafine","genericName":"terbinafine","approvalYear":"1992","relationship":"same-class"},{"drugId":"tolnaftate","brandName":"tolnaftate","genericName":"tolnaftate","approvalYear":"","relationship":"same-class"},{"drugId":"flucytosine","brandName":"flucytosine","genericName":"flucytosine","approvalYear":"1971","relationship":"same-class"},{"drugId":"naftifine","brandName":"naftifine","genericName":"naftifine","approvalYear":"1988","relationship":"same-class"},{"drugId":"tavaborole","brandName":"tavaborole","genericName":"tavaborole","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04531540","phase":"PHASE3","title":"Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-09-09","conditions":["Hypersensitivity"],"enrollment":225,"completionDate":"2013-10-18"},{"nctId":"NCT04532164","phase":"PHASE3","title":"Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-06-10","conditions":["Dermatitis, Photoallergic"],"enrollment":137,"completionDate":"2013-11-11"},{"nctId":"NCT04531527","phase":"PHASE3","title":"Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-06-24","conditions":["Dermatitis, Phototoxic"],"enrollment":32,"completionDate":"2013-06-28"},{"nctId":"NCT04531813","phase":"PHASE3","title":"Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-06-10","conditions":["Hypersensitivity"],"enrollment":32,"completionDate":"2013-07-01"},{"nctId":"NCT03999437","phase":"PHASE2","title":"SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS","status":"UNKNOWN","sponsor":"United Laboratories","startDate":"2019-01-02","conditions":["Tinea Pedis"],"enrollment":42,"completionDate":"2020-01-03"},{"nctId":"NCT01580878","phase":"PHASE1","title":"Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2012-01","conditions":["Tinea Pedis"],"enrollment":707,"completionDate":"2012-12"},{"nctId":"NCT01119742","phase":"PHASE1","title":"Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis","status":"TERMINATED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2010-07","conditions":["Interdigital Tinea Pedis"],"enrollment":428,"completionDate":"2011-07"},{"nctId":"NCT00835510","phase":"PHASE1","title":"Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2008-06","conditions":["Tinea Pedis"],"enrollment":548,"completionDate":"2008-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"Athletes Foot"},{"form":"CREAM","route":"TOPICAL","productName":"Athletes Foot Ultra"},{"form":"CREAM","route":"TOPICAL","productName":"Butenafine Hydrochloride"},{"form":"CREAM","route":"TOPICAL","productName":"Butenafine Hydrochloride 1%"},{"form":"CREAM","route":"TOPICAL","productName":"Butenafine Hydrochloride Athletes Foot"},{"form":"CREAM","route":"TOPICAL","productName":"Butenafine Hydrochloride Jock Itch"},{"form":"CREAM","route":"TOPICAL","productName":"Jock Itch"},{"form":"CREAM","route":"TOPICAL","productName":"Lotrimin Ultra"},{"form":"CREAM","route":"TOPICAL","productName":"Lotrimin Ultra Jock ItchAntifungal"},{"form":"CREAM","route":"TOPICAL","productName":"Lotrimin UltraAntifungal"},{"form":"CREAM","route":"TOPICAL","productName":"Lotrimin UltraAthletes Foot"},{"form":"CREAM","route":"TOPICAL","productName":"Lotrimin UltraJock Itch"},{"form":"CREAM","route":"TOPICAL","productName":"MENTAX"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000022059","MMSL":"14815","NDDF":"006293","UNII":"91Y494NL0X","VUID":"4024054","CHEBI":"CHEBI:3238","VANDF":"4021015","INN_ID":"6550","RXNORM":"236558","UMLSCUI":"C0107497","chemblId":"CHEMBL990","ChEMBL_ID":"CHEMBL990","KEGG_DRUG":"D01093","DRUGBANK_ID":"DB01091","PUBCHEM_CID":"2484","SNOMEDCT_US":"108923003","SECONDARY_CAS_RN":"101827-46-7","MESH_SUPPLEMENTAL_RECORD_UI":"C067594"},"formularyStatus":[],"originalProduct":{"form":"CREAM","route":"TOPICAL","company":"Mylan Pharmaceuticals Inc.","brandName":"MENTAX","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1996-","companyName":"Mylan","relationship":"Original Developer"},{"period":"present","companyName":"Bayer","relationship":"Current Owner"}],"publicationCount":119,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"D01AE23","allCodes":["D01AE23"]},"biosimilarFilings":[],"originalDeveloper":"Mylan","recentPublications":[{"date":"2026 Feb 23","pmid":"41730890","title":"Direct synthesis of bicyclo[1.1.1]pentane (BCP) boronates from carboxylic acids.","journal":"Nature communications"},{"date":"2026 Feb","pmid":"41400362","title":"An in vitro release test method with Immersion Cells for evaluation of drug release performance of butenafine hydrochloride cream.","journal":"Drug development and industrial pharmacy"},{"date":"2025 Aug 1","pmid":"41378809","title":"A Case of Tinea Nigra in Southern China.","journal":"The American Journal of dermatopathology"},{"date":"2025 Jul 15","pmid":"40733240","title":"Extended Antimicrobial Profile of Chromone-Butenafine Hybrids.","journal":"Molecules (Basel, Switzerland)"},{"date":"2025 Jul 25","pmid":"40657696","title":"Synthesis of N-Methylated Amines via Reduction of Carbamates Using Amidophosphine Borane.","journal":"The Journal of organic chemistry"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Sun Pharma Canada"],"status":"approved","companyName":"Bayer Healthcare Llc","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"1996","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-10-18T00:00:00.000Z","mah":"PHARMOBEDIENT","brand_name_local":"MENTAX","application_number":"NDA020524"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-12-31T00:00:00.000Z","mah":"MYLAN BERTEK","brand_name_local":"MENTAX","application_number":"NDA020663"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-05-02T00:00:00.000Z","mah":"BAYER HEALTHCARE LLC","brand_name_local":null,"application_number":"NDA021307"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-11-16T00:00:00.000Z","mah":"SUN PHARMA CANADA","brand_name_local":null,"application_number":"ANDA205181"},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:11:37.403669+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}